JP2007514756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514756A5 JP2007514756A5 JP2006545502A JP2006545502A JP2007514756A5 JP 2007514756 A5 JP2007514756 A5 JP 2007514756A5 JP 2006545502 A JP2006545502 A JP 2006545502A JP 2006545502 A JP2006545502 A JP 2006545502A JP 2007514756 A5 JP2007514756 A5 JP 2007514756A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- aryl
- heteroaryl
- group
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 28
- 201000010099 disease Diseases 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 208000032841 Bulimia Diseases 0.000 claims 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- -1 cyano, methoxy Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000001107 psychogenic effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003028 elevating effect Effects 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 0 *C(C(*)=NN12)=C(*)C1=NN=C(*)C2=O Chemical compound *C(C(*)=NN12)=C(*)C1=NN=C(*)C2=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53145103P | 2003-12-19 | 2003-12-19 | |
| PCT/US2004/042542 WO2005061509A1 (en) | 2003-12-19 | 2004-12-20 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007514756A JP2007514756A (ja) | 2007-06-07 |
| JP2007514756A5 true JP2007514756A5 (enExample) | 2007-12-20 |
Family
ID=34710226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545502A Pending JP2007514756A (ja) | 2003-12-19 | 2004-12-20 | カンナビノイド受容体モジュレーターとしてのアザ二環式へテロ環 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7037910B2 (enExample) |
| EP (1) | EP1699796A4 (enExample) |
| JP (1) | JP2007514756A (enExample) |
| CN (2) | CN1918164A (enExample) |
| AR (2) | AR046964A1 (enExample) |
| IS (1) | IS8501A (enExample) |
| NO (1) | NO20062689L (enExample) |
| PE (2) | PE20050756A1 (enExample) |
| TW (2) | TW200528455A (enExample) |
| WO (1) | WO2005061509A1 (enExample) |
| ZA (2) | ZA200604645B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
| EP2264014A1 (en) | 2001-08-31 | 2010-12-22 | Université Louis Pasteur | Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors |
| CA2550375A1 (en) | 2003-12-19 | 2005-07-14 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| US20060025448A1 (en) * | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
| EP1812007B1 (en) * | 2004-11-02 | 2011-09-07 | Northwestern University | Pyridazine compounds and methods |
| US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
| EP1999132B1 (en) | 2006-03-30 | 2012-07-18 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
| US20090325973A1 (en) | 2006-04-28 | 2009-12-31 | Watterson D Martin | Formulations containing pyridazine compounds |
| WO2007127474A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| KR20090013815A (ko) * | 2006-05-04 | 2009-02-05 | 솔베이 파마슈티칼스 비. 브이 | 충동 조절 장애의 치료를 위한 무스카린 작용제 |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| CN105250285B (zh) * | 2007-04-11 | 2019-09-06 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009137335A1 (en) * | 2008-05-05 | 2009-11-12 | The Scripps Research Institute | Synthesis of (+) corstistatin a and related compounds |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| FR2958850B1 (fr) * | 2010-04-14 | 2012-07-06 | Centre Nat Rech Scient | Medicaments pour la prevention ou le traitement des addictions aux drogues |
| ES2564352T3 (es) * | 2010-04-20 | 2016-03-22 | Università Degli Studi Di Roma "La Sapienza" | Derivados de tranilcipromina como inhibidores de la histona-desmetilasa LSD1 y/o LSD2 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
| CN103933569B (zh) * | 2013-01-22 | 2017-01-11 | 复旦大学 | 一种抗肺癌药物组合物及其应用、药盒和包装件 |
| CA2937967C (en) * | 2014-01-29 | 2022-07-26 | Neuropore Therapies, Inc. | Heteroaryl amides as inhibitors of protein aggregation |
| BR112018075039A2 (pt) | 2016-06-03 | 2019-05-14 | The Trustees Of Columbia University In The City Of New York | métodos de tratamento da síndrome de prader-willi |
| CN108178759B (zh) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | 一种α-肾上腺素受体拮抗剂的合成方法 |
| CN108498511A (zh) * | 2018-04-21 | 2018-09-07 | 徐晶 | 一种治疗膝关节骨性关节炎的药物组合物及其制备方法 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1164198B (it) | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
| AU6003099A (en) | 1998-10-06 | 2000-04-26 | Takeda Chemical Industries Ltd. | Fused pyridazine compounds, process for the preparation of the same and uses thereof |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| WO2003066061A1 (en) * | 2002-02-07 | 2003-08-14 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
| US7307164B2 (en) * | 2002-03-25 | 2007-12-11 | Merck & Co., Inc. | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7351826B2 (en) | 2003-02-19 | 2008-04-01 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
-
2004
- 2004-12-15 TW TW093138982A patent/TW200528455A/zh unknown
- 2004-12-15 TW TW093138971A patent/TW200530246A/zh unknown
- 2004-12-17 AR ARP040104771A patent/AR046964A1/es not_active Application Discontinuation
- 2004-12-17 AR ARP040104772A patent/AR047063A1/es not_active Application Discontinuation
- 2004-12-17 US US11/015,876 patent/US7037910B2/en not_active Expired - Lifetime
- 2004-12-17 CN CNA2004800419043A patent/CN1918164A/zh active Pending
- 2004-12-17 CN CNA2004800419202A patent/CN1918165A/zh active Pending
- 2004-12-20 EP EP04814691A patent/EP1699796A4/en not_active Withdrawn
- 2004-12-20 WO PCT/US2004/042542 patent/WO2005061509A1/en not_active Ceased
- 2004-12-20 JP JP2006545502A patent/JP2007514756A/ja active Pending
-
2005
- 2005-01-03 PE PE2005000014A patent/PE20050756A1/es not_active Application Discontinuation
- 2005-01-03 PE PE2005000013A patent/PE20051047A1/es not_active Application Discontinuation
-
2006
- 2006-06-06 ZA ZA200604645A patent/ZA200604645B/xx unknown
- 2006-06-08 IS IS8501A patent/IS8501A/xx unknown
- 2006-06-09 ZA ZA200604778A patent/ZA200604778B/xx unknown
- 2006-06-12 NO NO20062689A patent/NO20062689L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514756A5 (enExample) | ||
| JP2016500063A5 (enExample) | ||
| JP2010526807A5 (enExample) | ||
| JP5487202B2 (ja) | 新規甲状腺ホルモンβ受容体作動薬 | |
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN111285829B (zh) | 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途 | |
| JP2005508318A5 (enExample) | ||
| JP5847533B2 (ja) | 新規甲状腺ホルモンβ受容体作動薬 | |
| JP2020515636A5 (enExample) | ||
| JP2009542699A5 (enExample) | ||
| JP2009542702A5 (enExample) | ||
| JP2019524784A5 (enExample) | ||
| TW200408620A (en) | Substituted amides | |
| JP2009528375A5 (enExample) | ||
| WO2006086445A2 (en) | Combination therapy | |
| JP2008521829A5 (enExample) | ||
| CN102600162A (zh) | 哒嗪衍生物及其作为治疗剂的用途 | |
| JP4915715B2 (ja) | フェニルピリダジン誘導体及びこれを含有する医薬 | |
| EP2655368A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| JP2007500720A5 (enExample) | ||
| TW201121544A (en) | Novel phenol derivative | |
| JP2017524005A5 (enExample) | ||
| JP2008526888A5 (enExample) | ||
| JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP2011521962A5 (enExample) |